Tanvex BioPharma Inc (6541) - Total Assets
Based on the latest financial reports, Tanvex BioPharma Inc (6541) holds total assets worth NT$7.64 Billion TWD (≈ $240.64 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 6541 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Tanvex BioPharma Inc - Total Assets Trend (2013–2025)
This chart illustrates how Tanvex BioPharma Inc's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Tanvex BioPharma Inc for net asset value and shareholders' equity analysis.
Tanvex BioPharma Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Tanvex BioPharma Inc's total assets of NT$7.64 Billion consist of 18.8% current assets and 81.2% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 11.0% |
| Accounts Receivable | NT$123.23 Million | 1.6% |
| Inventory | NT$416.48 Million | 5.2% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$485.32 Million | 6.1% |
| Goodwill | NT$2.91 Billion | 36.6% |
Asset Composition Trend (2013–2025)
This chart illustrates how Tanvex BioPharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Tanvex BioPharma Inc (6541) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tanvex BioPharma Inc's current assets represent 18.8% of total assets in 2025, a decrease from 37.5% in 2013.
- Cash Position: Cash and equivalents constituted 11.0% of total assets in 2025, down from 34.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 42.0% of total assets, an increase from 8.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 36.6% of total assets.
Tanvex BioPharma Inc Competitors by Total Assets
Key competitors of Tanvex BioPharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Tanvex BioPharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.33 | 2.89 | 4.97 |
| Quick Ratio | 0.84 | 2.38 | 4.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$276.13 Million | NT$981.53 Million | NT$1.15 Billion |
Tanvex BioPharma Inc - Advanced Valuation Insights
This section examines the relationship between Tanvex BioPharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.90 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 191.1% |
| Total Assets | NT$7.96 Billion |
| Market Capitalization | $311.40 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tanvex BioPharma Inc's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Tanvex BioPharma Inc's assets grew by 191.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Tanvex BioPharma Inc (2013–2025)
The table below shows the annual total assets of Tanvex BioPharma Inc from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$7.96 Billion ≈ $250.82 Million |
+191.07% |
| 2024-12-31 | NT$2.74 Billion ≈ $86.17 Million |
-1.02% |
| 2023-12-31 | NT$2.76 Billion ≈ $87.06 Million |
-19.19% |
| 2022-12-31 | NT$3.42 Billion ≈ $107.74 Million |
-27.45% |
| 2021-12-31 | NT$4.71 Billion ≈ $148.50 Million |
+7.80% |
| 2020-12-31 | NT$4.37 Billion ≈ $137.76 Million |
+22.38% |
| 2019-12-31 | NT$3.57 Billion ≈ $112.57 Million |
-20.22% |
| 2018-12-31 | NT$4.48 Billion ≈ $141.11 Million |
+12.73% |
| 2017-12-31 | NT$3.97 Billion ≈ $125.17 Million |
+2.60% |
| 2016-12-31 | NT$3.87 Billion ≈ $122.00 Million |
+146.74% |
| 2015-12-31 | NT$1.57 Billion ≈ $49.45 Million |
+139.70% |
| 2014-12-31 | NT$654.74 Million ≈ $20.63 Million |
+34.37% |
| 2013-12-31 | NT$487.27 Million ≈ $15.35 Million |
-- |
About Tanvex BioPharma Inc
Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. It also engages in contract development and manufacturing of biological medicine… Read more